Provided is a sustained-release triptan composition as a suitable depot formulation to carry a therapeutically effective amount of triptan for administration via subcutaneous or intramuscular injection. This sustained-release triptan composition is characterized by a high drug to phospholipid ratio and provides an improved pharmacokinetic profile in vivo. The sustained-release triptan composition is for use as a medicament in the treatment of migraine or cluster headache.本申請案提供一種緩釋型翠普登組成物，可經皮下或肌肉注射給藥，作為一種適合攜帶具療效劑量之翠普登類藥物的儲存型製劑。此緩釋型翠普登組成物之特徵為其藥物對磷脂質的莫耳比率高，且能提供一較佳的活體藥物動力學特性。所述的緩釋型翠普登組成物係作為一藥物，用於治療偏頭痛或叢發性頭痛。
